Catherine Harper‐Wynne

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Andrew Tutt, Holly Tovey, Maggie C.U. Cheang et al. · Nature Medicine · 2018 · 903 citations · Full text

Medicine, Oncology, Pharmacology +11

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer

Nicholas C. Turner, Claire Swift, Ben Jenkins et al. · Annals of Oncology · 2022 · 191 citations · Full text

Medicine, Molecular Medicine, Oncology +17

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

Mitch Dowsett, Catherine Harper‐Wynne, Irene Boeddinghaus et al. · PubMed · 2001 · 173 citations

Medicine, Endocrinology, Oncology +14

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)

Andrew Tutt, Lucy Kilburn, Cheryl Gilett et al. · Cancer Research · 2015 · 166 citations

Medicine, Oncology, Pharmacotherapy +17